Baker Avenue Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Baker Avenue Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-32,800	Closed	-$489K	–	1592
2023 Q3	$489K	Sell	32,800 -20,000	-38%	-$265K	0.02%	264
2023 Q2	$578K	Hold	52,800	–	–	0.03%	252
2023 Q1	$460K	Hold	52,800	–	–	0.02%	272
2022 Q4	$331K	Hold	52,800	–	–	0.02%	289
2022 Q3	$185K	Hold	52,800	–	–	0.01%	328
2022 Q2	$156K	Hold	52,800	–	–	0.01%	300
2022 Q1	$164K	Buy	+52,800	New	+$166K	0.01%	287
2021 Q3	–	Sell	-52,800	Closed	-$230K	–	280
2021 Q2	$230K	Hold	52,800	–	–	0.01%	225
2021 Q1	$239K	Hold	52,800	–	–	0.01%	219
2020 Q4	$303K	Sell	52,800 -9,700	-16%	-$73.4K	0.02%	198
2020 Q3	$452K	Buy	62,500 +15,000	+32%	+$80.2K	0.03%	171
2020 Q2	$166K	Buy	+47,500	New	+$137K	0.01%	230

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baker Avenue Asset Management's CBAY Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 32,800 shares — an estimated $489K sold.

Baker Avenue Asset Management first reported a position in CBAY in Q2 2020 and held it in 12 quarters. The position peaked at $578K in Q2 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Baker Avenue Asset Management reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
Baker Avenue Asset Management sold 32,800 Cymabay Therapeutics shares in Q4 2023, an estimated $489K.
Baker Avenue Asset Management first reported a position in Cymabay Therapeutics in Q2 2020 and held it in 12 quarters.
Baker Avenue Asset Management's Cymabay Therapeutics position peaked at $578K in Q2 2023.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.